Elevated Oncology (ELEV) Climbs 57%
(Updated – May 26, 2023 10:50am EST)
Elevated Oncology (ELEV) Climbs 57%
- Point72 hedge fund recently disclosed an 8.7% stake in the company
- Today’s gain appears to be related to ASCO’s early-stage stomach cancer treatment data. The abstract was for “First-of-its-kind dose escalation and expansion study of SYSA1801, an antiviral complex targeting claudin 18.2 in patients with refractory/refractory solid tumors.”
